Switch theme
Sign up to access all valuation multiples
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
2020
25
LTM Revenue $0.4M
Last FY EBITDA -$60.4M
-$41.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Rallybio has a last 12-month revenue (LTM) of $0.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Rallybio achieved revenue of $0.6M and an EBITDA of -$60.4M.
Rallybio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Rallybio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.4M | XXX | $0.6M | XXX | XXX | XXX |
| Gross Profit | $0.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$60.4M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -9491% | XXX | XXX | XXX |
| EBIT | -$53.0M | XXX | -$60.5M | XXX | XXX | XXX |
| EBIT Margin | -12329% | XXX | -9512% | XXX | XXX | XXX |
| Net Profit | -$49.6M | XXX | -$57.8M | XXX | XXX | XXX |
| Net Margin | -11543% | XXX | -9084% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Rallybio's stock price is $0.
Rallybio has current market cap of $12.9M, and EV of -$41.5M.
See Rallybio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$41.5M | $12.9M | XXX | XXX | XXX | XXX | $-1.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Rallybio has market cap of $12.9M and EV of -$41.5M.
Rallybio's trades at -65.2x EV/Revenue multiple, and 0.7x EV/EBITDA.
Equity research analysts estimate Rallybio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Rallybio has a P/E ratio of -0.3x.
See valuation multiples for Rallybio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.9M | XXX | $12.9M | XXX | XXX | XXX |
| EV (current) | -$41.5M | XXX | -$41.5M | XXX | XXX | XXX |
| EV/Revenue | -96.6x | XXX | -65.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBIT | 0.8x | XXX | 0.7x | XXX | XXX | XXX |
| EV/Gross Profit | -96.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.3x | XXX | -0.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRallybio's last 12 month revenue growth is -81%
Rallybio's revenue per employee in the last FY averaged $25K, while opex per employee averaged $2.4M for the same period.
Rallybio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Rallybio's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Rallybio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -81% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -9491% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -9573% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $25K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6526% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 9612% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rallybio acquired XXX companies to date.
Last acquisition by Rallybio was XXXXXXXX, XXXXX XXXXX XXXXXX . Rallybio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Rallybio founded? | Rallybio was founded in 2020. |
| Where is Rallybio headquartered? | Rallybio is headquartered in United States of America. |
| How many employees does Rallybio have? | As of today, Rallybio has 25 employees. |
| Who is the CEO of Rallybio? | Rallybio's CEO is Dr. Stephen Uden, M.D.. |
| Is Rallybio publicy listed? | Yes, Rallybio is a public company listed on NAS. |
| What is the stock symbol of Rallybio? | Rallybio trades under RLYB ticker. |
| When did Rallybio go public? | Rallybio went public in 2021. |
| Who are competitors of Rallybio? | Similar companies to Rallybio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Rallybio? | Rallybio's current market cap is $12.9M |
| What is the current revenue of Rallybio? | Rallybio's last 12 months revenue is $0.4M. |
| What is the current revenue growth of Rallybio? | Rallybio revenue growth (NTM/LTM) is -81%. |
| What is the current EV/Revenue multiple of Rallybio? | Current revenue multiple of Rallybio is -96.6x. |
| Is Rallybio profitable? | Yes, Rallybio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
